Raffaella Pippa
Overview
Explore the profile of Raffaella Pippa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quaglia F, Krishn S, Daaboul G, Sarker S, Pippa R, Domingo-Domenech J, et al.
J Extracell Vesicles
. 2020 Sep;
9(1):1761072.
PMID: 32922691
The ability of small extracellular vesicles (sEVs) to reprogram cancer cells is well established. However, the specific sEV components able to mediate aberrant effects in cancer cells have not been...
2.
Dominguez Andres A, Feng Y, Campos A, Yin J, Yang C, James B, et al.
bioRxiv
. 2020 Aug;
PMID: 32839770
One-sentence Summary: SARS-CoV-2 ORF9c is the first human coronavirus protein localized to membrane, suppressing antiviral response, resembling full viral infection.
3.
Pippa R, Odero M
Cells
. 2020 Mar;
9(3).
PMID: 32110991
The MYC transcription factor is one of the best characterized PP2A substrates. Deregulation of the MYC oncogene, along with inactivation of PP2A, are two frequent events in cancer. Both proteins...
4.
Arriazu E, Vicente C, Pippa R, Peris I, Martinez-Balsalobre E, Garcia-Ramirez P, et al.
Blood Cancer J
. 2020 Jan;
10(1):3.
PMID: 31913266
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy. Although novel emerging drugs are available, the overall prognosis remains poor and new therapeutic approaches are required. PP2A phosphatase is a...
5.
Pippa R, Boffo S, Odero M, Giordano A
J Cell Physiol
. 2019 Dec;
235(6):5284-5292.
PMID: 31858592
Mesothelioma is an aggressive tumor that affects thousands of people every year. The therapeutic options for patients are limited; hence, a better understanding of mesothelioma biology is crucial to improve...
6.
Vicente C, Arriazu E, Martinez-Balsalobre E, Peris I, Marcotegui N, Garcia-Ramirez P, et al.
Cancer Lett
. 2019 Oct;
468:1-13.
PMID: 31593801
Acute myeloid leukemia (AML) is an aggressive disease associated with very poor prognosis. Most patients are older than 60 years, and in this group only 5-15% of cases survive over...
7.
Rodriguez-Bravo V, Pippa R, Song W, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, et al.
Cell
. 2018 Aug;
174(5):1200-1215.e20.
PMID: 30100187
Nuclear pore complexes (NPCs) regulate nuclear-cytoplasmic transport, transcription, and genome integrity in eukaryotic cells. However, their functional roles in cancer remain poorly understood. We interrogated the evolutionary transcriptomic landscape of...
8.
Pippa R, Dominguez A, Malumbres R, Endo A, Arriazu E, Marcotegui N, et al.
Oncotarget
. 2017 Sep;
8(33):53989-54003.
PMID: 28903318
The SET (I2PP2A) oncoprotein is a potent inhibitor of protein phosphatase 2A (PP2A) that regulates many cell processes and important signaling pathways. Despite the importance of SET overexpression and its...
9.
Endo A, Ly T, Pippa R, Bensaddek D, Nicolas A, Lamond A
J Biol Chem
. 2016 Nov;
292(1):172-184.
PMID: 27872192
Tumor invasion into surrounding stromal tissue is a hallmark of high grade, metastatic cancers. Oncogenic transformation of human epithelial cells in culture can be triggered by activation of v-Src kinase,...
10.
Richard N, Pippa R, Cleary M, Puri A, Tibbitts D, Mahmood S, et al.
Oncotarget
. 2016 Oct;
7(51):84214-84227.
PMID: 27705940
Recent evidence suggests that inhibition of protein phosphatase 2A (PP2A) tumor suppressor activity via the SET oncoprotein contributes to the pathogenesis of various cancers. Here we demonstrate that both SET...